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Estimation of Dose-Response Functions for
Longitudinal Data
Erica E M Moodie and David A. Stephens
Abstract
In a longitudinal study of dose-response, the presence of confounding or non-
compliance compromises the estimation of the true effect of a treatment. Stan-
dard regression methods cannot remove the bias introduced by patient-selected
treatment level, that is, they do not permit the estimation of the causal effect of
dose. Using an approach based on the Generalized Propensity Score (GPS), a
generalization of the classical, binary treatment propensity score, it is possible
to construct a balancing score that provides a more meaningful estimation pro-
cedure for the true (unconfounded) effect of dose. Previously, the GPS has been
applied only in a single interval setting. In this paper, we extend the GPS method-
ology to the longitudinal setting. The methodology is applied to simulated data
and two real data sets; first, we study the Riesby depression data, and secondly
we present analysis of a recent study, the Monitored Occlusion Treatment of Am-
blyopia Study (MOTAS), which investigated the dose-response relationship in an
ophthalmological setting between occlusion and improvement in visual acuity.
The MOTAS study was revolutionary as it was the first to accurately measure
occlusion dose received by the child.
1. Introduction
In observational studies of the efficacy of a treatment, there is the potential for bias in the
estimation of the treatment effect whenever the treatment dose level is influenced by subject-
specific covariates. Also, randomized trials, particularly those where treatment is given over
time in several treatment intervals, must contend with partial or total non-compliance, which
effectively renders the trial observational. Statistical analyses in the face of non-compliance
have often relied on intention-to-treat or as-treated analyses, which respectively ignore the
dose actually received or do not account for the informative nature of non-compliance. The
aim of this paper is to provide a framework for examining the effect of treatment given over
time with incomplete adherence or at a patient-controlled level.
1.1. Longitudinal Observational Dose-Response Studies
Two approaches may be of interest when analyzing longitudinal data. The first assumes
a repeated measures structure, with each participant providing repeated time-varying co-
variate data over a number of intermediate measurements as well as a final, end-of-study
health measurement, and where the response is taken to be the vector of health outcome
measurements. The second focuses on the by-interval changes, taking as the response the
vector of changes in health outcomes between successive measurements. Where a by-interval
approach provides a meaningful response, its use may simplify the analysis by reducing or
even removing any serial correlation which may be present in the data. Using the vector
of differences in response also has the advantage of allowing the analyst to fit a common
curve in all intervals (for example, a linear dose-response with a common intercept as well
as slope). Arjas and Parner (2004) provide a recent review of the main statistical issues that
arise when estimating causal effects from observational longitudinal data.
In this paper, we focus on a by-interval approach, and estimate the cross-sectional effect
of dosing by examining the change in response that may be attributed to a unit of dose in
an interval. With data in this form, a regression approach may at first seem to provide a
reasonable basis for analysis. This strategy, however, takes no account of subject-controlled
treatment level, which we interpret as non- or partial compliance, which is a potential source
of bias in the estimation of treatment effect. In this paper, we develop methods that address
issues of confounding and non-compliance using a balancing score approach based on the
Generalized Propensity Score (GPS) (Imbens, 2000; Hirano and Imbens, 2004) for a contin-
uous treatment that controls for sources of such bias. The GPS has received relatively little
attention in statistical circles; however, see Flores (2004) for an economics application.
As noted by Rubin (2007), observational studies and randomized trials are part of a con-
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tinuum, due to potential confounding of the dose received in randomized studies due to
non-compliance. In the context of randomized trials, causal methods have been proposed
which are based on principal stratification by the compliance score (Follman, 2000; Fran-
gakis and Rubin, 1999, 2002); see Joffe et al. (2003) for a comprehensive explanation and
discussion. In such an approach, a compliance score, a predictive model for compliance with
assigned treatment given baseline covariates, is used (frequently as a matching variable) to
estimate the complier average causal effect (CACE), that is, the effect treatment among
individuals who would comply with a prescribed treatment dose. Adjustments for compli-
ance based only on pre-treatment variables will typically be unable to identify the effect of
a treatment taken over time, as compliance may vary as a function of response to treat-
ment. Furthermore, as we will demonstrate, a univariate scoring approach is not capable of
accounting for all possible forms of confounding in the longitudinal setting.
Causal methods for estimating treatment effects from repeated measures data are available
but not readily implemented for continuous doses. Neugebauer and van der Laan (2006),
for example, propose a G-computation procedure. However the procedure is computation-
ally expensive and so the authors discretized the continuous treatment. Another causal
procedure for repeated measures data uses Marginal Structural Models (MSMs) (Robins
et al., 2000; Herna´n et al., 2000). MSMs use inverse weighting by the treatment mechanism
model to remove bias and estimate the marginal effect of time-varying treatment regimes on
a univariate response. MSMs were originally designed to estimate the effects of static (not
covariate-adapted) time-varying treatments, but were recently proposed as a method to com-
pare dynamic regimes which may have been found by other estimation procedures (Herna´n
et al., 2006) and further extended to estimate the optimal dynamic regime Bembom and
van der Laan (2007). Marginal Structural Models can be used for continuous treatments,
although this is not common in practice, in much the same way that the GPS is an under-
recognized and under-used tool the single time-point setting. In a single interval, the MSM
approach is very closely related to the Generalized Propensity Score analysis procedure.
Finally, research into estimating dynamic treatment regimes – that is, finding the best
covariate-specific treatments – has been a particularly active area in causal inference for
longitudinal data. Murphy (2003) and Robins (2004) published seminal material on meth-
ods for estimating optimal treatment rules, which are reviewed by Moodie et al. (2007).
1.2. Objectives and Structure of Paper
In this paper, we extend a causal modelling approach to account for the within-person
correlation of responses, the within-person correlation of doses, and the potential confounding
of the cross-sectional effect of dose on response by previous doses.
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The paper is structured as follows: Section 2. introduces notation and the Generalized
Propensity Score methodology. Section 3. extends the balancing score approach to incor-
porate the complexities of a repeated measures structure with time-varying covariates. The
repeated measures GPS is compared with traditional regression methods and the univariate
GPS via simulation in section 4.. Section 4.3. provides an example of GPS analyses applied
to a familiar data set, the Reisby et al. (1977) study of depressed patients treated using the
drug imipramine. Section 5. discusses and concludes.
2. A Balancing Score Approach to Estimating a
Dose-Response Relationship
To ascertain the true effect of dose, a causal analysis which accounts for the potential con-
founding between dose levels and other measured covariates is desirable. One tool used to
account for possible confounding relationships between occlusion treatment and other co-
variates is the Generalized Propensity Score (Imbens, 2000; Imai and Van Dyk, 2004; Hirano
and Imbens, 2004), a variable that can be used for stratification or explicitly in a regression
analysis that removes bias in the estimation of the treatment effect. A regression which
includes the GPS does not provide a parameter that may be interpreted causally (see the
discussion below), however it can be used to obtain estimates of the potential response to
a dose which does have a causal interpretation. The balancing property of the GPS may
provide greater confidence that the analysis has successfully eliminated potential bias due to
(measured) confounding.
2.1. The Generalized Propensity Score
In the following formulation of the Generalized Propensity Score model, we presume that the
dose/response pairs are conditionally independent, that is, we ignore the repeated measures
nature of the data. In Section 3., we extend the framework to one suitable for the analysis
of longitudinal observational data.
Suppose that we have collected data repeatedly on N individuals, so that ni, i  1, ..., N
measurements are available. We denote the total number of data points n 
°N
i1 ni, the
response Y , the treatment dose D, and other potentially confounding covariates X; we denote
observed values of these random variables y, d and x respectively. We define D to be the
set of possible doses, a bounded interval in R. In this section, we restrict our attention to
the case where ni  1, so the response data are simply Yk P tYij : i  1, . . . , N, j  1u and
n  N .
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The causal analysis is formulated through the use of potential or counterfactual outcomes,
that is, the value of the response that would result if a subject were to receive a specified
treatment dose not necessarily the same as the dose they received in the study. We denote
by Ykpdq  YkpDk  dq the potential response random variable resulting from a dose Dk  d
taken in an interval, and write ykpdq for the observed version. Potential outcomes adhere to
the axiom of consistency : the actual and potential response are equal when the regime in
question is the dose actually received, that is, ykpdq  yk if d  dk.
As with all models for observational data, causal models require certain modelling assump-
tions to be appropriately specified (Robins, 1997; Robins et al., 2000). Specifically, we make
the stable unit treatment value assumption (Rubin, 1978), which states that a subject’s out-
come is not influenced by other subjects’ treatment allocation. We further assume weak
unconfoundedness of the potential outcomes given the covariates, so that Ykpdq K Dk|Xk for
all d P D; see Hirano and Imbens (2004).
Following Imbens (2000) and Hirano and Imbens (2004), we define the observed Generalized
Propensity Score (GPS), rpd, xq for dose d and covariate values x by
rpd, xq  fD|Xpd|xq, (1)
that is, the conditional density function for D given X  x evaluated at D  d; R  rpD,Xq
is the corresponding random quantity. The GPS is an extension of the propensity score
(Rosenbaum and Rubin, 1983) to continuous treatments. In this paper, we regard the
construction of this conditional density as a regression problem, and regress D on X. Note
here that, if d1  d0, then we may have rpd1, x1q  rpd0, x0q even if x1  x0.
The GPS R, its observed version rk  rpdk, xkq, and potential version rd,k  rpd, xkq for
d P D form part of the bias removal strategy. As is shown by Hirano and Imbens (2004), the
GPS random quantity R has two properties that render it useful in causal inference problems.
First, R acts as a balancing score - D and X are conditionally independent given R; this
result implies that within strata of R, the distribution of dose is the same irrespective of the
value of the covariate. Secondly, the distribution of the potential response is independent of
the covariates, given the treatment and the propensity score - for all sets A,
PrrY pdq P A|D  d,R,Xs  PrrY pdq P A|D  d,Rs.
That R breaks the dependence between D and X is the crucial factor that permits causal
inference; the conditional independence of Y and X given D and R permits simplified mod-
elling. We shall see that both features carry over to the longitudinal setting.
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2.2. Average Potential Outcomes
To report the causal effect of interest, we thus examine the conditional average causal effect
of dose D, defined as the difference in expected outcomes for two dose levels d0, d1 for fixed
covariate values Xk  x, that is
ErYkpd1q|Xk  xs  ErYkpd0q|Xk  xs. (2)
The average causal effect is the expectation of this quantity over the distribution of different
X values in the study population. The modelling of outcome on dose and the GPS, R (rather
than X), returns an estimate of
ErYkpd1q|Rk  rs  ErYkpd0q|Rk  rs (3)
and its population average. The GPS does not return estimates of the quantity in equation
(2), but does yield a bias-removal strategy: we examine the conditional distribution of Y
given D and R, rather than the conditional distribution given D and X, and recover a con-
sistent estimator of the dose-response relationship by averaging appropriately. Specifically, a
key quantity of interest in dose-response modelling is the Average Potential Outcome (APO)
at dose level d, µpdq, where
µpdq  ErY pdqs  EXrErY pdq|Xss,
which traces the causal dose-response relationship as d varies inD. We shall see that equation
(3) facilitates consistent estimation of the dose-response relationship, as we may average the
conditional expectations over the distribution of R if the balancing property holds, that is,
if within-score strata the conditional density value for D  d does not depend on X. The
adequacy of any proposed propensity score model rests on whether or not balance is achieved,
but can be checked by standard exploratory statistical methods.
2.3. An Algorithm for Estimating the APO
The role of the propensity score in estimating the APO is made clear by the identity given
in Imbens (2000)
µpdq  ErY pdqs  EXrErY pdq|Xss  EXrErY pdq|rpd,Xqss,
where, for fixed dose d, the iterated expectation over Y given X and D, then X, is replaced
by an iterated expectation over Y and R and D, then X, utilizing the fact that for fixed
X and D, R is completely determined. We outline the estimation procedure, essentially
5
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described in Hirano and Imbens (2004), here.
I. Form the GPS Model: Using a regression approach, construct a predictive model,
fD|Xpd|x, βq, for D given X. Estimate parameters β, from the observed dose and
covariate data.
II. Compute the Fitted GPS values: Compute the estimated GPS, prk  fD|Xpdk|xk, pβq.
III. Form the Observable Model: Using a regression approach, construct a predic-
tive model, fY |D,Rpy|d, r, αq, for Y given D and R. Estimate parameters α using
tpyk, dk, prkq, k  1, . . . , Nu.
IV. Estimate the APO: Estimate the APO at dose level d by
pµpdq  pErY |D  ds  1
n
n¸
k1
EY |D,RrYkpdq|D  d, prk  prpd, xkq, pαs
for d P D, where pr is evaluated at β  pβ. Then pµpdq, d P D is the GPS-adjusted
estimated dose-response function.
Justification for this procedure is given in Hirano and Imbens (2004), and is extended in
Section 3.. The two key conditional models fD|Xpd|x, βq and fY |D,Rpy|d, r, αq, or the corre-
sponding conditional moments, must be user-specified, but the adequacy of both components
can be assessed in a straightforward statistical fashion.
We note that any one-to-one function of the GPS provides the desired balancing property, so
that in fY |D,Rpy|d, r, αq, mean response may depend on R, categories defined by discretizing
R, or some more general one-to-one function of R. In particular, an alternative approach
proposed by Hirano and Imbens (2004) suggests that in practice, the APO may be approx-
imated by estimating the dose-response effect within strata defined by the linear predictor
of the treatment density function, and then combining these estimates to form a single,
weighted average. This approach is often more straightforward to implement than the above
algorithm and often provides an estimate of the dose-response relationship that has little or
no biased (see Section 4.).
3. The GPS for Repeated Measures Data
In the case of dose-response estimation from repeated measures or multi-interval data, the
potential patterns of confounding are more complex than can be dealt with using a univariate
GPS approach. In this section, we formulate a GPS approach suitable for the analysis of
6
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repeated measures response data with interval-dependent dosing. In our by-interval analysis,
where interest lies in the estimating the response to dose received within an interval, we will
assume that the marginal distribution of the counterfactual response, Y pdq, is the same for
all intervals, so that we have a single dose-response function µpdq  ErY pdqs to estimate.
The method is amenable to more general models, however.
In the repeated measures setting, we no longer wish to ignore the correlation structure in
the data, and so we return to the use of notation that makes this explicit. We therefore
have that Yij, i  1, ..., N , j  1, ..., ni is the response for individual i in interval j; dose
and covariate variables are similarly subscripted. Furthermore, we modify the notion of
weak unconfoundedness to what we term sequential weak unconfoundedness; dropping the
subscript i for convenience, we assume
Yjpdq K Dj|X1, ..., Xj.
That is, at each interval, assignment to dose d is weakly unconfounded with the change in
visual acuity during interval j given covariates, previous response, and dose values measured
up to the start of the jth interval. We denote the history of covariates, response, and previous
doses by qXj  pX1, ..., XjqT .
The GPS procedure must be modified in the case of repeated measures data, in both the
construction of the propensity score itself, and in the estimation of the APO. Consider
the vector of observed propensity scores, r, formed by concatenating the interval-specific
observed propensity scores rj  fD| qXjpdj|qxjq for each j. Given r, the conditional expectation
in the Observable Model can be estimated using Generalized Least Squares the regression
model where for individual i,
ErYipdq|ri,dis  Xiα
where Xi is the design matrix combining vectors ri and di for individual i.
We now demonstrate that the repeated measures GPS procedure retains the desired bal-
ancing properties of the univariate approach. The theoretical properties of the repeated
measures GPS are extended from an adaptation of those in Hirano and Imbens (2004) to
cover the multivariate setting. The result for the single interval setting can be recovered
from the theorem as a special case.
Theorem 1 (Weak Unconfoundedness Given the Repeated Measures GPS). Sup-
pose that assignment to treatment in the jth interval is sequentially weak unconfounded given
variables qXj that occurred prior to treatment in the current interval (and may include pre-
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vious treatment doses). Then, for every dose d,
fD|Rd,jpd|rd,jq  fD|Rd,j ,Yd,jpd|rd,j, yd,jq.
where Yd,j  Yjpdq and yd,j  yjpdq.
Proof: Sequential weak unconfoundedness implies that for all d P D, Yjpdq K Dj| qXj, that
is, for each dose d, Yj and Dj are conditionally independent given qXj. Consider the random
quantities, Rj  rpDj, qXjq, where rpd, qxjq  fD|Xpd|qxjq, and Rd,j  rpd, qXjq, defined for
fixed d. Denoting by f the density function for the relevant random variables, we have
fD|Rd,jpd|rd,jq 
»
Xd,j
fD, qXj |Rd,jpd, qxj|rd,jq dqxj 
»
Xd,j
fD| qXj ,Rd,jpd|qxj, rd,jqf qXj |Rd,jpqxj|rd,jq dqxj
where Xd,j  Xj is the set of solutions qxj of the equation rd,j  rpd, qxjq. Now, on Xd,j,
fD| qXj ,Rd,jpd|qxj, rd,jq  fD| qXjpd|qxjq  rd,j, as for fixed d and qxj on the contour, rd,j is
completely defined. Thus
fD|Rd,jpd|rd,jq 
»
Xd,j
rd,jf qXj |Rd,jpqxj|rd,jq dqxj  rd,j
»
Xd,j
f
qXj |Rd,j
pqxj|rd,jq dqxj  rd,j  fD| qXjpd|qxjq
for an archetypal qxj on Xd,j. Similarly, by weak unconfoundedness,
fD|Rd,j ,Yd,jpd|rd,j, yd,jq 
»
Xd,j
fD| qXj ,Rd,j ,Yd,jpd|qxj, rd,j, yd,jqf qXj |Rd,j ,Yd,jpqxj|rd,j, yd,jq dqxj

»
Xd,j
fD| qXjpd|qxjqf qXj |Rd,j ,Yd,jpqxj|rd,j, yd,jq dqxj

»
Xd,j
rd,jf qXj |Rd,j ,Yd,jpqxj|rd,j, yd,jq dqxj  rd,j  fD| qXjpd|qxjq
for an archetypal qxj on Xd,j. Thus, for all d, fD|Rd,jpd|rd,jq  fD|Rd,j ,Yd,jpd|rd,j, yd,jq and we
have weak unconfoundedness given Rd,j  rpd, qXjq.
Theorem 2 (Bias Removal of the Repeated Measures GPS Procedure). Suppose
that µpdq  ErY pdqs be the marginal mean of interest. For interval j, consider the mean
βpd, rd,jq  ErYjpdq|D  d,Rd,j  rd,js
that conditions on the GPS. The Average Potential Outcome, obtained by averaging βpd, rd,jq
over the observed distribution of the covariates qXj, is an unbiased estimator of the dose-
response function µpdq.
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Proof: By conditional probability and Theorem 1 above,
fYd,j |D,Rd,jpyd,j|d, rd,jq 
fYd,j |Rd,jpyd,j|rd,jqfD|Yd,j ,Rd,jpd|yd,j, rd,jq
fD|Rd,jpd|rd,jq

fYd,j |Rd,jpyd,j|rd,jqfD|Rd,jpd|rd,jq
fD|Rd,jpd|rd,jq
 fYd,j |Rd,jpyd,j|rd,jq
so that ErYjpdq|D  d,Rd,j  rd,js  ErYjpdq|Rd,j  rd,js. However,
ErYjpdq|D  d,Rd,j  rd,js  ErYjpdq|D  d, rpD, qXjq  rd,js
 ErYjpdq|D  d, rpd, qXjq  rd,js
 ErYjpdq|D  d,Rd,j  rd,js  βpd, rd,jq
using the first result. Thus, by iterated expectation, noting that ErY pdqs  ErYjpdqs,
µpdq  ErYjpdqs  ERd,j rErYjpdq|Rd,j  rd,jss  ERd,j rβpd,Rd,jqs  E qXj rβpd, rpd,
qXjqqs.
Corollary: By Theorem 2, applying the bias removal result sequentially to each interval,
we obtain an unbiased estimator of µpdq after pooling results over all intervals, by taking the
expectation in turn over qX1, qX2, . . ..
NOTE : A univariate GPS analysis that does not construct R by conditioning on qXj  qxj
for each j does not necessarily achieve bias removal.
4. Simulation Studies and Examples
4.1. Simulation I: Nonlinear, nonadditive treatment effect
Here, we extend the artificial example of Hirano and Imbens (2004) to a two-interval setting.
The causal structure of the model is depicted in Figure 1.
Data generation: Suppose that at the first and second interval, we have
Y1pdq|X11, X12  N pd  pX11  X12q exprdpX11  X12qs, 1q
Y2pdq|X21, X12  N pd  pX21  X12q exprdpX21  X12qs, 1q
Suppose that the marginal distributions of each of X11, X12, and X21 are all unit exponential,
and the marginal mean of the response in either interval is identical. As in Hirano and Imbens
9
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(2004), the APO can be obtained by integrating out the covariates analytically, yielding
µpdq  d 
2
p1   dq3
.
A multivariate GPS analysis, will involve the concatenated GPS vector RM  pR1, R2q
T
where R1  pX11   X12q exprDpX11   X12qs and R2  pX21   X12q exprDpX21   X12qs,
which consists of correctly-specified models. A univariate, or cross-sectional, GPS analysis
might fail to include information from the previous interval and hence the GPS used would
be RU  pR1, R

2q
T where R1 is as before, but R

2  X21 exprDX21s.
Analysis and Results: We generated 1,000 datasets of size 250, 500, 100, and 10,000. The
mean and median APO/dose-response curves using the MGPS were exactly correct, while
the UPGS analysis (see Figure 2 for results with n  250) was clearly biased. The general
shape of the UGPS APO was correct, however the curve fell outside of the confidence bands
of the (unbiased) MGPS over part of the range of doses even with samples as small as 250.
4.2. Simulation II: Nonlinear, nonadditive confounding
We now demonstrate the need for repeated measures GPS model by considering a plausible
potential confounding mechanism. Suppose that data are distributed according to the causal
structure defined in Figure 3. That is, treatment dose received in an interval is caused by
(or is a descendant of) the response level Y measured prior to the dose being taken and of
dose taken in the previous interval (when not in the first treatment interval).
We generalize the univariate setting used by others (Rubin and Thomas, 2000; Imai and
Van Dyk, 2004), in which the exponential function is used to specify a mean model which
the effects of the confounding variables on Y in each interval are nonlinear and nonadditive.
Data Generation: At each interval j, j  1, 2, variables Xj1, Xj2, Xj3, Xj4 are measured.
The variables Xj1, X3, and Xj4 are Normally distributed, while Xj2 is a Bernoulli random
10
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variable. At each interval, treatment dose Dj and response Yj are distributed as follows:
D1 
1
100
p400.9  0.8X211   1.6X12  0.65X13q   1
Y1  18.7   2.3D1   expp0.8X11   2.3X12  1.1X13q 
Irexpp0.8X11   2.3X12  1.1X13q   50s  4.2X14   10ξ1
D2 
1
100
p400.9  0.8X221   1.6X22  0.65X23q   Y1   2
Y2  18.7   2.3D2   expp0.8X21   2.3X22  1.1X23  0.2Y1q 
Irexpp0.8X21   2.3X22  1.1X23  0.2Y1q   50s  4.2X24   10ξ2
where 1, ξ1, 2, ξ2  N p0, 1q are mutually independent. The coefficients in these models were
chosen arbitrarily, with indicator functions included to prevent extremely large responses.
Let Y  pY1, Y2q
T , D  pD1, D2q
T , and Xl  pX1l, X2lq
T , for l  1, 2, 3, 4. We may dis-
tinguish these covariates as variables which confound, Xc  pX1, X2, X3q, and the variable
which only predicts response (not treatment), Xp  X4.
Analyses: We apply the univariate and multivariate GPS functions assuming a Normal
distribution of dose, and in each of analyses – a non-causal regression model, a univariate
GPS approach, and a multivariate GPS approach – the mean model for response in an interval
will be (incorrectly) assumed to be linear. A fourth approach will also be considered: the
approximation to the APO suggested by Imai and Van Dyk (2004) based on the multivariate
GPS model. Specifically, we perform the following five analyses:
1. Linear model: ErY s is fit as a linear function of D, Xc, and Xp.
2. Univariate GPS (UGPS): ErDs is fit as a linear function of Xc and used to construct
the GPS RU ; ErY s is fit as a linear function of D, RU , and Xp.
3. Repeated measures, or multivariate, GPS (MGPS Linear): ErD1s is fit as a linear
function of X11, X12, X13, and X14 while ErD2s is fit as a linear function of X21, X22,
X23, X24, and Y1. These models are used to construct the GPS R
M , consisting of the
concatenated Generalized Propensity Scores at each interval. ErY s is fit as a linear
function of D, RM , and Xp.
4. Repeated measures GPS (MGPS Quintiles): The GPS RM is estimated as in (3)
above, however the GPS is now used to create dummy variables for membership in
each quintiles of the observed GPS values. ErY s is fit as a linear function of D, the
variables for quintile membership, and Xp.
11
Hosted by The Berkeley Electronic Press
5. Repeated measures GPS (Linear Predictor Quintiles): The GPS RM is estimated
as in (3) above, however the linear predictor of the GPS is used to create dummy
variables for membership in each quintiles of the observed GPS values. ErY s is fit as
a linear function of D, the variables for quintile membership, and Xp.
The univariate GPS approach, which controls for the confounding attributable to the covari-
ates but ignores potential confounding by previous responses, will provide adequate balance
for estimating the cross-sectional effect of dose at the first interval but will not provide the
required balance in the second interval, where confounding of the cross-sectional relationship
between D2 and Y2 by Y1 is observed. The repeated measures GPS, when constructed so
as to correctly model the causal structure of the data, has the same balancing properties as
the univariate GPS, in that within strata of R, the distribution of D does not depend on
X. However, both GPS analyses rely on the incorrectly specified mean models for both dose
and response. The (non-causal) linear is also mis-specified. One thousand data sets were
generated for sample sizes 250, 500, 1000, and 10,000.
Results: In all sample sizes, the repeated measures GPS approach using the GPS as a
linear term in the response model produced unbiased estimates of the true dose effect: at
the smallest sample size (n  250), bias was less than 0.91%, and dropped to 0.08% with
n  10, 000. The repeated measures GPS approach using the GPS to construct dummy
variables of quintile membership exhibited bias of about 3-5%, followed distantly by the
univariate GPS approach (18%) and the linear model (20-21%). The repeated measures GPS
approach using the linear predictor of the GPS to construct dummy variables of quintile
membership were virtually identical to those using the quintiles of the GPS (results not
shown); this is to be expected when the GPS model provides a reasonable fit to the doses.
It is interesting to note that the linear model, the univariate GPS, and the repeated measures
GPS (linear GPS) approach all produce unbiased estimates of the effect of the predictor of
response, X4, which does not predict treatment. The bias was less than 0.5% with each of
the aforementioned approaches. The variability of the estimate from the linear model was
smallest, though only slightly less than the variability of the repeated measures GPS (linear
GPS). The repeated measures GPS approach using quintile membership produced highly
biased estimates of the effect of X4 on response.
The performance of the repeated measures GPS approach using quantiles of the GPS as
dummy variables may be improved by taking a greater number of quantiles. Using deciles
rather than quantiles provides dose-effect estimates that exhibit very little bias (below 3%).
The variability of the dose-effect estimate using this approach is, however, larger than that
found by including the GPS as a continuous variable.
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4.3. Example I: Riesby Depression Study
Reisby et al. (1977) treated 66 hospitalized depressed patients for four weeks with 225 mg/day
imipramine; patients were classified as having endogenous or non-endogenous depression.
Antidepressive effect was evaluated on the basis of the post-treatment rating scores. We
analyze the effect of imipramine concentration measured weekly on the change in depression,
as assessed by the Hamilton’s Depression Rating Scale (HDRS).
Analysis: The concentration of imipramine in the blood plasma is approximately Normally
distributed on the log scale. A univariate GPS analysis was performed using log-imipramine
concentration as a linear function of patient sex and depression type (endogenous or not)
and an interaction between these variables, and then estimating the APO using a linear
regression of the change in HDRS on log-imipramine concentration and the univariate GPS.
An MGPS analysis was also performed under the assumption of first-order Markov property
for the log-imipramine concentrations. That is, log-imipramine concentrations within (and
between) patients were assumed to be conditionally independent, given the HDRS score at
the start of the week, patient sex, and depression type. The repeated measures APO was
computed using a linear mixed effect model, regressing the change in HRS on log-imipramine
concentration and the repeated measures GPS and allowing for random intercepts.
Results: Both the univariate and repeated measures GPS analyses indicate that depres-
sion decreases with increasing blood concentrations of imipramine on the range of 0.47 -
1.75 units (or 1.60-5.75 log-units), as observed in Figure 4. The dose-response relationship
shows an approximately linear decrease in symptoms across the range of log concentrations
observed. The univariate and repeated measures analyses produce nearly identical dose-
response curves. This is not surprising, as exploratory plots revealed very little correlation
between HDRS at the start of the week and either the log-imipramine concentration during
the week or the change in HDRS during the week.
While few covariates were available for this analysis, raising the possibility of unmeasured
confounding, it was plausible a priori that the Riesby data follow a structure akin to that
in Figure 3. That is, the change in depression score may be caused by the current level of
depression and as well as the drug received.
One might speculate whether the concentration of imipramine in the previous interval also
confounds the relationship between change in HDRS and the most recent concentration of
imipramine. Exploratory plots reveal a strong correlation between drug concentration from
one interval to the next, but virtually none between change in HDRS and the concentration
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of imipramine in the previous interval. Recent work in the binary-treatment propensity
score literature suggests that including variables which predict treatment but are unrelated
to response can create bias (Austin et al., 2007; Brookhart et al., 2006), therefore imipramine
concentration in the previous interval was not included in the either of the GPS models.
4.4. Example II: MOTAS Amblyopia Study
Amblyopia is the most common childhood vision disorder, and is characterized by reduced
visual function in one eye. A standard treatment for the condition is occlusion therapy,
that is, patching of the functioning fellow eye. The apparent beneficial effect of occlusion
therapy has never been well quantified, partly due to difficulty in the accurate measurement
of the occlusion dose. The Monitored Occlusion Treatment of Amblyopia Study (MOTAS)
(Stewart et al., 2004) was the first clinical study aimed at quantifying the dose-response
relationship of occlusion, facilitated by the use of an electronic occlusion dose monitor.
The MOTAS design and a full description of the study base have been published previously
(Stewart et al., 2002, 2004). At study entry, all children who required spectacles entered the
refractive adaptation phase; the remainder entered the occlusion phase directly. Children
still considered amblyopic after refractive adaption began occlusion and were prescribed six
hours of occlusion daily. Visual acuity was measured on the logarithm of Minimum Angle
of Resolution (logMAR) scale; improvement is indicated by a decrease in logMAR. Visual
function and monitored occlusion dose were recorded at approximately two-week intervals
until acuity ceased to improve. A total of 116 children were enrolled in MOTAS; we analyze
data of the 68 who took part in the occlusion phase who, although prescribed six hours of
occlusion daily, received varying occlusion doses because of incomplete concordance.
Notation for MOTAS: For child i, the response, Yij, is the change visual acuity during
interval j for patient i, and Dij be the random occlusion dose (in hours) received in interval
j. Let Aij be the age in months at the start of interval j and Lij and Pi denote the visual
acuity at the start of interval j and at the start of the phase, respectively.
In the study, dose is a continuous variable, but 60 out of 404 (about 15%) of intervals in
the occlusion phase had a zero dose. The GPS model fD|Xpd|x, βq must acknowledge the
mixture nature of the dose distribution, so we assume that, given X  x,
D
L
 pipx, γqIrd  0s   p1  pipx, γqqIrd  0sD  (4)
where D  is a strictly positive random variable whose distribution depends on X  x and
β, and 0   pipx, γq   1 is a mixing weight. Estimation in this model is straightforward
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when a parametric distribution is used for D , and such regression model that induces a
balancing property can be used. To estimate γ, we fit a logistic regression model to the
binary (D  0{D ¡ 0) dose data.
Recent work has shown that optimal (binary treatment) propensity scores include all con-
founding variables and variables that predict outcome, while variables that are purely pre-
dictors of treatment should not be included in the model (Brookhart et al., 2006; Austin
et al., 2007). The following covariates therefore included: visual acuity at start of interval,
L, interval number, length of interval (in days), and amblyopic type (anisometropic, stra-
bismic, mixed). These covariates were used to predict both the probability of having any
occlusion at all (D{D ¡ 0) in a logistic model and the probability of receiving a particular
dose (greater than zero) of occlusion in a Weibull model. The GPS used was
prpd, xq  ppipx, pγqIrd  0s   p1  ppipx, pγqqIrd  0sfpd|x, pφ, pβq
where fpd|x, φ, βq is a Weibull density with shape φ and scale exptxTβuq. For the GPS to
act as a balancing score, the distribution of D should not depend on qX within strata of rˆ.
The balancing property appears to have been approximately achieved.
As response in the MOTAS is the vector of changes in visual acuity, there is little observed
serial correlation in the data, so we ignore the repeated measures nature of the data. The
observable model for change in visual acuity, Y , is modelled via the expectation
EY |D,RrY |D  d,R  r, αs  α0   Irr   0.1spα1   α2d  α3r   α4d.rq . (5)
This model can be readily extended to a more flexible or piecewise constant partition model.
However, here, the addition of higher order terms led to only minimal changes in the infer-
ences made. Also, when using a mixture distribution such as (4) for the GPS, it may be that
the pr values for one component differ substantially from those of the other, so that there
are no data in a portion of the space consisting of all pd, rq-pairs for d P D, r P rangep pRq
where rangep pRq denotes the range of estimated generalized propensity scores. We account
for this explicitly in the model; rather than fitting a model that assumes that the relationship
between response and dose and the GPS is the same function in regions of the plane where
pd, rq pairs were observed, and in regions where no data was observed. Using the model in
equation (5), we obtain least-squares estimates (SE) pα0 = -0.018 (0.008), pα1  0.009 (0.041),pα3  -3.19-04 (3.24e-04), pα3  -0.083 (4.042), and pα4  -0.101 (0.080), respectively.
Results of the UGPS Analysis: A plot of the dose-response curve is presented in Figure
5(a). This plot indicates that the association between dose and visual acuity, when confound-
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ing between dose and the covariates is adjusted for using the GPS approach, is appreciable;
the average potential effect on change in visual acuity measurement Y is significantly nega-
tive (corresponding to vision improvement) over the entire range of positive doses considered.
A numerical summary is given in Table 2.
A plot of the average (over the covariate distribution) dose effect estimated by a non-causal
mixed effects model analysis is presented in Figure 5(a) for comparison. The intercept of the
causal APO is nearer to zero than the regression ADE, in agreement with ophthalmological
belief that visual acuity will not improve spontaneously in the absence of occlusion. Also,
the APO suggests a plateau, or a saturation of the effect of occlusion in an interval at about
80 hours. This indicates that children may not exhibit a clinically meaningful improvement
in visual acuity with more than, on average, six hours of occlusion per day over a two-week
period. This conclusion is entirely reasonable, as physical changes to the amblyopic eye that
can occur in a fixed time period are likely limited by biological processes.
Applying the MGPS to the MOTAS Data: There is evidence in the data to suggest
considerable correlation between dose of occlusion in an interval and that received in the
previous interval (estimated correlation, unadjusted for within-person clustering, is 0.45).
We adopt a first-order Markov model, and model dose in each interval as a function of the
dose received in the previous interval. We adopt a GPS model similar to the model in
equation (4) modified for the longitudinal setting; for interval j,
Dj
L
 pipqxj, dj1, γqIrdj  0s   p1  pipqxj, dj1, γqqIrdj  0sDj 
with, again, a Weibull model dependent on qXj, Dj1 for the continuous part of the distribu-
tion and use logistic regression model to the binary (D  0{D ¡ 0) dose data.
The following covariates were included: occlusion dose in the previous interval, visual acuity
at start of interval, L, interval number, length of interval (in days), and amblyopic type. Co-
efficient estimates (SE) are displayed in Table 3. A graphical check of whether the balancing
property was achieved raised no concerns. The observable model in equation (5) was again
adopted. Parameters were estimated using a linear mixed effects model with a random inter-
cept to account for any correlation that may exist in the response (though little is expected,
as the response measures the change in visual acuity). Using the model in equation (5), we
obtain estimates (SE) pα0 = -0.020 (0.008), pα1  -0.002 (0.040), pα2  -3.05e-4 (3.19e-4), pα3 
0.218 (4.103), and pα4  -0.062 (0.085), respectively.
Results of the MGPS Analysis: A plot of the dose-response curve is presented in Figure
5(b); a numerical summary of the APO based on a repeated measures GPS analysis is
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provided in Table 4. The average change in visual acuity due to occlusion predicted by the
repeated measures GPS modelling is very similar to that predicted by the univariate GPS
model. The similarity of results is due to the fact that the univariate GPS provided the
required balancing property, and so little additional reduction in bias was anticipated. It
appears that in MOTAS, dose in the previous interval is highly correlated with current dose
of occlusion, but not strongly associated with current change in visual acuity.
5. Discussion
In a longitudinal study of dose-response, full compliance is the exception rather than the
expected. To estimate the dose-response relationship with confidence, modelling potentially
confounding relationships flexibly is key. Generalized Propensity Scores are under-used in
the cross-sectional (single time-point) setting, and yet provide a tractable and flexible option
of analysis, and can be adapted to any number of complex dosing strategies. We have
extended the GPS methodology to the repeated measures setting to cope with situations
where treatment doses received in different intervals are correlated and response may depend
on doses in current and earlier intervals.
In applying the repeated measures GPS approach, one must take care over the issue of the
intercept of the causal dose-response curve. For example, if in the Riesby example response
was taken to be depression rating score rather than the change in depression score, the dose-
response curve estimated over all intervals similarly would be averaging a series of parallel
dose response curves with different intercepts (since, from interval to interval, the average
depression would show improvement due to dose in the previous interval).
Whether analyzing data from a cross-sectional study or in repeated measures setting, it is
essential to consider a response model that is flexible in its dependence on the GPS or to
use the approximate method of estimating the APO. The GPS often incorporates covariate
information into the mean model for response in a highly nonlinear fashion. An incorrectly-
specified mean model may not provide a good estimate of the true dose-response curve, even
if the GPS has successfully achieved the desired balancing of confounding variables.
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Table 1: Simulation II results: Coefficient estimates (standard errors) for the parameters
from a linear model, a univariate GPS analysis (UGPS), and multivariate GPS analyses
(MGPS) where the GPS is included as a linear term in the response model or quintiles of
the GPS are included as factor level variables in a linear model. The true coefficient of D is
2.3 in all cases.
n Model: Linear model UGPS MGPS MGPS
(Linear) (Quintiles)
250 Intercept -11.60 (3.83) -36.15 (29.15) -6.17 (8.66) -13.68 (5.21)
D 1.810 (0.559) 1.889 (0.565) 2.321 (1.093) 2.210 (1.279)
X1 -1.262 (1.018)
X2 3.710 (2.082)
X3 -1.942 (2.157)
X4 -4.187 (0.710) -4.189 (0.700) -4.187 (0.698) -2.680 (14.142)
GPS 5.625 (7.572) -2.566 (2.490)
500 Intercept -11.58 (2.34) -46.90 (26.10) -6.76 (6.51) -13.46 (3.57)
D 1.817 (0.405) 1.898 (0.404) 2.297 (0.554) 2.221 (0.867)
X1 -1.276 (0.506)
X2 3.730 (1.186)
X3 -1.884 (0.803)
X4 -4.199 (0.469) -4.197 (0.485) -4.195 (0.485) -3.049 (5.365)
GPS 8.405 (6.789) -2.380 (1.820)
1000 Intercept -11.57 (1.88) -54.34 (22.56) -7.65 (4.76) -13.59 (2.49)
D 1.816 (0.306) 1.895 (0.306) 2.286 (0.383) 2.178 (0.620)
X1 -1.275 (0.392)
X2 3.721 (0.932)
X3 -1.908 (0.673)
X4 -4.192 (0.397) -4.190 (0.408) -4.190 (0.409) -3.040 (3.494)
GPS 10.339 (5.865) -2.138 (1.347)
10,000 Intercept -11.59 (0.55) -63.24 (8.45) -9.79 (2.26) -13.40 (0.80)
D 1.836 (0.108) 1.916 (0.108) 2.298 (0.131) 2.189 (0.407)
X1 -1.297 (0.138)
X2 3.774 (0.321)
X3 -1.943 (0.239)
X4 -4.205 (0.122) -4.206 (0.125) -4.207 (0.126) -3.305 (1.128)
GPS 12.624 (0.125) -1.595 (0.622)
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Table 2: MOTAS Data: Summaries of the APO (on the logMAR scale) from a univariate
GPS model analysis for changing dose amount per interval: 5000 bootstrap samples.
Dose (hours)
Quantile 10 25 50 75 100
Frequentist 2.5 -0.036 -0.051 -0.077 -0.091 -0.104
25 -0.025 -0.039 -0.063 -0.076 -0.085
50 -0.020 -0.033 -0.056 -0.069 -0.076
75 -0.014 -0.028 -0.049 -0.062 -0.068
97.5 -0.003 -0.017 -0.037 -0.050 -0.053
Table 3: MOTAS Data: Estimates and standard errors for the parameters from the repeated
measures (first-order Markov) GPS model: the model comprised a logistic regression for
D  0 versus D ¡ 0) and a Weibull model for positive dose.
Model: Any dose Continuous dose
Term Est. (SE) Est. (SE)
Intercept -2.527 (0.514) 3.665 (0.231)
Previous dose -0.014 (0.002) 1.209 (0.104)
Visual acuity (L) 0.247 (0.470) 0.556 (0.178)
Interval number 0.220 (0.048) 0.025 (0.018)
Interval length 0.013 (0.007) 0.003 (0.005)
Type: mixed -1.812 (0.447) -0.354 (0.209)
Type: strabismic -0.239 (0.445) -0.168 (0.216)
Table 4: MOTAS Data: Summaries of the APO (on the logMAR scale) from a repeated
measures GPS model analysis for changing dose amount per interval: 5000 bootstrapsamples.
Dose (hours)
Quantile 10 25 50 75 100
Frequentist 2.5 -0.040 -0.054 -0.087 -0.105 -0.116
25 -0.025 -0.042 -0.072 -0.089 -0.097
50 -0.018 -0.035 -0.064 -0.080 -0.088
75 -0.011 -0.029 -0.056 -0.072 -0.079
97.5 0.005 -0.018 -0.042 -0.056 -0.062
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Figure 1: Simulation Study I: Directed Acyclic Graph of the longitudinal structure of simu-
lated data for a nonlinear, nonadditive treatment effect generative model.
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Figure 2: Simulation Study I: Pointwise median APO from univariate GPS (UGPS) and
repeated measures GPS analyses (MGPS) with point-wise 95% credible intervals the MGPS
APO for a nonlinear, nonadditive treatment effect generative model.
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Figure 3: Simulation Study II: Directed Acyclic Graph of the longitudinal structure of
simulated data for a generative model with nonlinear, nonadditive confounding:
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Figure 4: Riesby Data: The estimated average potential change in Hamilton Depression Rat-
ing Scale (HDRS) for log-imipramine blood concentrations in the range of 1.60 to 5.75 units
with point-wise 95% credible intervals for univariate GPS (UGPS) and repeated measures
GPS analyses (MGPS). Observed dose values indicated along the horizontal axis.
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(a) Univariate GPS
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(b) Multivariate GPS
Figure 5: MOTAS Data: The estimated average potential change in visual acuity (APO) for
doses in the range of 1 to 100 hours per interval with point-wise 95% credible interval. In
(a), the univariate GPS (UGPS) APO of Section 2. with the average dose effect (ADE) from
a non-causal regression model included for comparison. In (b), the repeated measures GPS
(MGPS) APO of Section 3. is plotted, with the UGPS APO included in gray for comparison.
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